Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
BRIDGEWATER, N.J., Jan. 04, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the 35th Annual J.P. Morgan Healthcare Conference on January 9-12, 2017 in San Francisco. Will Lewis, president and chief executive officer of Insmed, will deliver a corporate overview on Wednesday, January 11 at 7:30 AM PT.
Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral inhibitor of dipeptidyl peptidase I with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled prodrug formulation of treprostinil that may offer a differentiated product profile for rare pulmonary disorders. For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Investor Contact: Laura Perry Argot Partners 646.439.0410 [email protected]
